Purdue Pharma denies EY conflicts of interest, fraudulent transfers
Bankrupt US OxyContin maker Purdue Pharma has denied claims its plan to hire EY would create a conflict of interest, as it fights fraudulent transfer claims raised in the US Supreme Court.
To read more
Subscribe to Global Restructuring Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Restructuring Review experts.